180 Life Sciences Corp. (ATNF)
- Previous Close
1.1800 - Open
1.2000 - Bid 1.0300 x 100
- Ask 1.1200 x 100
- Day's Range
1.0505 - 1.2000 - 52 Week Range
0.6580 - 17.7500 - Volume
50,928 - Avg. Volume
146,214 - Market Cap (intraday)
6.151M - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-15.4900 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
180lifesciences.comRecent News: ATNF
View MorePerformance Overview: ATNF
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATNF
View MoreValuation Measures
Market Cap
6.15M
Enterprise Value
1.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.87%
Return on Equity (ttm)
-135.21%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.18M
Diluted EPS (ttm)
-15.4900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.59M
Total Debt/Equity (mrq)
1.67%
Levered Free Cash Flow (ttm)
-3.18M